The “Deep Draw Container Forming Method” developed by Mystic Pharmaceuticals for packaging of intranasal drugs for use with its VersiDoser and VRx2 intranasal delivery systems has been awarded US Patent No. 7,963,089. Both delivery systems use the proprietary unit dose blister packaging. The VersiDoser uses liquid-filled blisters, while the VRx2 reconstitutes freeze dried formulations prior to delivery.
Mystic President and CEO Timothy Sullivan commented: “Mystic’s delivery platforms are a breakthrough for adherence packaging in the ophthalmic drug delivery market. Unit dose packaging combined with our self administered delivery systems set a new standard for improving patient compliance and treatment outcomes.”
The company says that the combined packaging and delivery systems allow for packaging of an equivalent number of dose with 70% less bulk drug volume compared to standard systems. Mystic offers development and manufacturing services for pharmaceutical companies interested in using its technology.
Read the Mystic press release.
